Alnylam Pharmaceuticals Stock (NASDAQ: ALNY)

Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

ALNYLAM PHARMACEUTICALS INC

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 15 years by 10.3% on an annualized basis producing an average annual return of 22.67%. Currently, Alnylam Pharmaceuticals has a market capitalization of $42.15 billion. 
Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 15 years ago, it would be worth $2,138.15 today based on a price of $325.64 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753310714_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

ALNY

Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Needham analyst Gil Blum downgraded the rating for Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Hold to Underperform. Sarepta Therapeutics shares closed at $14.07 on Friday. <a href="https://www.benzinga.com/quote/srpt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Seth Sigman downgraded Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) from Equal-Weight to Underweight and announced a $91 price target. Target shares closed at $103.46 on Friday. <a href="https://www.benzinga.com/quote/tgt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Swann analyst Mani Foroohar downgraded Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Outperform to Market Perform and cut the price target from $45 to $10. Sarepta Therapeutics shares closed at $14.07 on Friday. <a href="https://www.benzinga.com/quote/srpt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities analyst Patrick Scholes downgraded Royal Caribbean Cruises Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) from Buy to Hold but raised the price target from $275 to $337. Royal Caribbean shares closed at $350.10 on Friday. <a href="https://www.benzinga.com/quote/rcl/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>TD Cowen analyst Ryan Langston downgraded Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Buy to Hold and cut the price target from $73 to $33. Centene shares closed at $27.95 on Friday. <a href="https://www.benzinga.com/quote/cnc/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying TGT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="579" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21083022/image-278-1024x579.png" alt="" class="wp-image-993565" style="width:569px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21083022/image-278-1024x579.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21083022/image-278-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21083022/image-278-768x434.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21083022/image-278.png 1142w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46491269/top-2-energy-stocks-that-may-fall-off-a-cliff-this-quarter-2">Top 2 Energy Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>
Photo via Shutterstock

Downgrades

Pre-Market Outlook

Markets

Analyst Ratings

SRPT

This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>JP Morgan analyst Drew Chamberlain initiated coverage on Argan, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGX#NYSE">AGX</a>) with a Neutral rating and announced a price target of $220. Argan shares closed at $206.63 on Friday. <a href="https://www.benzinga.com/quote/agx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital analyst Mike Dahl initiated coverage on QXO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NYSE">QXO</a>) with an Outperform rating and announced a price target of $33. QXO shares closed at $21.63 on Friday. <a href="https://www.benzinga.com/quote/qxo/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays initiated coverage on Albertsons Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) with an Underweight rating and announced a price target of $19. Albertsons shares closed at $20.47 on Friday. <a href="https://www.benzinga.com/quote/aci/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital analyst Mark Schappel initiated coverage on Autodesk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Hold rating and announced a price target of $320. Autodesk shares closed at $297.03 on Friday. <a href="https://www.benzinga.com/quote/adsk/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities analyst Danielle Brill initiated coverage on Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy rating and announced a price target of $385. Alnylam Pharmaceuticals shares closed at $320.53 on Friday. <a href="https://www.benzinga.com/quote/alny/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ALNY stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/ALNY/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="623" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21082308/image-277-1024x623.png" alt="" class="wp-image-993559" style="width:600px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21082308/image-277-1024x623.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21082308/image-277-300x182.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21082308/image-277-768x467.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21082308/image-277.png 1097w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46491269/top-2-energy-stocks-that-may-fall-off-a-cliff-this-quarter-2">Top 2 Energy Stocks That May Fall Off A Cliff This Quarter</a> </li>
</ul>
Photo via Shutterstock

Initiation

ADSK

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Truist Securities analyst Danielle Brill initiates coverage on Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy rating and announces Price Target of $385.

Price Target

Truist Securities Initiates Coverage On Alnylam Pharmaceuticals with Buy Rating, Announces Price Target of $385

10 analysts have expressed a variety of opinions on Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $357.7, a high estimate of $404.00, and a low estimate of $325.00. Marking an increase of 10.61%, the current average surpasses the previous average price target of $323.40. 
<img src="https://www.benzinga.com/files/images/story/2025/1752671215_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of Alnylam Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$348.00</td>
<td>$338.00</td>
</tr>
<tr>
<td>David Lebovitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$404.00</td>
<td>$364.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$359.00</td>
<td>$336.00</td>
</tr>
<tr>
<td>Maury Raycroft</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$384.00</td>
<td>$328.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$333.00</td>
<td>$287.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$377.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Kostas Biliouris</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$360.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$338.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Esther Rajavelu</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$349.00</td>
<td>$331.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$325.00</td>
<td>$300.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Alnylam Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Alnylam Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Alnylam Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALNY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Alnylam Pharmaceuticals analyst ratings.</a>
<h2>Delving into Alnylam Pharmaceuticals's Background</h2>
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
<h3>A Deep Dive into Alnylam Pharmaceuticals's Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Alnylam Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 20.2% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Alnylam Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -9.67%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Alnylam Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -62.98%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Alnylam Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.36%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a high debt-to-equity ratio of 11.28, Alnylam Pharmaceuticals faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Alnylam Pharmaceuticals Through 10 Analysts

JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Overweight and raises the price target from $338 to $348.

JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $348

Citigroup analyst David Lebovitz maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $364 to $404.

Citigroup Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $404

B of A Securities analyst Tazeen Ahmad maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $336 to $359.

B of A Securities Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $359

Jefferies analyst Maury Raycroft maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $328 to $384.

Jefferies Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $384

OXLUMO has been shown to significantly reduce urinary oxalate, which drives the progression of PH1 Disease
MISSISSAUGA, ON, July 2, 2025 /CNW/ -&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4458268-1&amp;h=820107370&amp;u=http%3A%2F%2Fwww.alnylam.com%2F&amp;a=Alnylam+Canada+ULC">Alnylam Canada ULC</a> is pleased to announce that OXLUMO&#xAE; (lumasiran) is now funded across Canada through both public and private plans. OXLUMO is an RNA interference (RNAi) therapeutic administered via subcutaneous injection, indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in paediatric and adult patients.
OXLUMO is the first therapy for PH1 approved in Canada, and among the first medications to be included on the common list of new drugs for rare diseases, as part of the Government of Canada's National Strategy for Drugs for Rare Diseases. The common list was developed to help patients with rare diseases have access to treatments as early as possible.

Alnylam Canada Says OXLUMO Is Now Funded Across Canada Through Both Public And Private Plans For Treatment Of PH1 In Pediatric And Adult Patients

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) is currently in Phase 10 of its 18-phase Adhishthana Cycle. With this phase scheduled to end in September 2025, the stock remains within its bullish structure. If that structure holds, the peak is likely to form in Phase 11, the classic culmination point of the Adhishthana Himalayan formation.
<h3 class="wp-block-heading">The Gap-Up Move &amp; Current Phase: Technical and Structural Alignment</h3>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="814" height="522" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01101105/ALNY-Stock-Weekly-Chart.png" alt="Fig.1 ALNY Stock Weekly Chart (Source: Adhishthana.com Reports)" class="wp-image-15137" style="width:524px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01101105/ALNY-Stock-Weekly-Chart.png 814w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01101105/ALNY-Stock-Weekly-Chart-300x192.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01101105/ALNY-Stock-Weekly-Chart-768x493.png 768w" sizes="(max-width: 814px) 100vw, 814px" /><figcaption class="wp-element-caption">Fig.1 ALNY Stock Weekly Chart (Source: Adhishthana.com Reports)</figcaption></figure>
On June 24, ALNY gapped up by more than 30% after announcing that its drug Vutrisiran, used to treat transthyretin amyloid cardiomyopathy, delivered successful results. While the headline reason was fundamental, under the Adhishthana lens, this wasn't a random event.
The stock was in Phase 9 at the time, a phase known for triggering supreme moves and powerful shifts in structure. Phase 9 is also where the stock typically breaks out of its Adhishthana Cakra and begins forming the Himalayan structure. That's exactly what happened here. The gap-up and event aligned itself with the principles, both in sentiment and in form. Now in Phase 10, the stock is continuing its upward trajectory, holding firmly within a bullish stance.
<h3 class="wp-block-heading">Peak Formation Timing: Phase 10 Still in Play</h3>
According to the Adhishthana Principles, peak formation in Phase 10 generally occurs between the 18th and 23rd bars of the phase. ALNY, however, has yet to show any signs of a peak, suggesting the structure is still building. (Ref Fig 1)
As long as this setup remains intact, Phase 11 is likely to host the eventual peak followed by a correction.
<h3 class="wp-block-heading">Monthly Chart Insights: Cakra Formation and Nirvana Level</h3>
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="594" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01101605/ALNY-Cakra-Formtaion-Monthly-Adhishthana--1024x594.png" alt="Fig.2 ALNY Stock Monthly Chakra Formation (Source: Adhishthana.com Reports)" class="wp-image-15141" style="width:529px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01101605/ALNY-Cakra-Formtaion-Monthly-Adhishthana--1024x594.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01101605/ALNY-Cakra-Formtaion-Monthly-Adhishthana--300x174.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01101605/ALNY-Cakra-Formtaion-Monthly-Adhishthana--768x446.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01101605/ALNY-Cakra-Formtaion-Monthly-Adhishthana-.png 1196w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Fig.2 ALNY Stock Monthly Chakra Formation (Source: Adhishthana.com Reports)</figcaption></figure>
On the monthly timeframe, ALNY is currently in Phase 6, a phase associated with the creation of the Nirvana level, which acts as both a value barometer and a magnet during future bearish periods.
The Nirvana level is yet to be finalized but will be structurally created on September 30, 2025. Current chart dynamics suggest the Nirvana zone is likely to emerge around $240, which will become a long-term reference point.
Also worth noting: starting from Phase 4, the stock has been forming its monthly Adhishthana Cakra, and is now trading near the upper arc of this structure. According to the framework, the underlying trades in this range with a breakout emerging in Phase 9. Considering this and the fact that Phase 10 is approaching maturity on the weekly chart, signs of exhaustion may emerge soon.
<h3 class="wp-block-heading">Investor Outlook: Hold with Caution, Avoid New Entries for Now</h3>
For existing investors, the strategy is to hold while closely monitoring the weekly chart for ALNY signs of a structural breakdown. A clear break would signal the beginning of the descent phase- the "Wrath of Ganga" in Adhishthana terminology, bringing the stock back toward its Nirvana level.
For potential entrants, Phase 10 is not an ideal entry zone, especially with the stock trading near the higher arc of the monthly Adhishthana Cakra. Chasing the momentum at this point would offer poor risk-reward dynamics.

Equities

Technicals

Opinion

Signals

Alnylam Pharma Stock Outlook: Is ALNY Topping Out?

Analysts' ratings for Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) over the last quarter vary from bullish to bearish, as provided by 9 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Alnylam Pharmaceuticals, revealing an average target of $352.22, a high estimate of $500.00, and a low estimate of $268.00. Surpassing the previous average price target of $330.22, the current average has increased by 6.66%.
<img src="https://www.benzinga.com/files/images/story/2025/1751310017_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Alnylam Pharmaceuticals among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$333.00</td>
<td>$287.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$377.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Kostas Biliouris</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$360.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$338.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Esther Rajavelu</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$349.00</td>
<td>$331.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$325.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Michael Ulz</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$268.00</td>
<td>$284.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$500.00</td>
<td>$500.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Alnylam Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Alnylam Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Alnylam Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALNY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Alnylam Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Alnylam Pharmaceuticals Better</h2>
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
<h3>A Deep Dive into Alnylam Pharmaceuticals's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Alnylam Pharmaceuticals's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 20.2%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -9.67%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Alnylam Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -62.98%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Alnylam Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.36%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a high debt-to-equity ratio of 11.28, Alnylam Pharmaceuticals faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Alnylam Pharmaceuticals Through 9 Analysts

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 5 years by 2.17% on an annualized basis producing an average annual return of 16.39%. Currently, Alnylam Pharmaceuticals has a market capitalization of $41.78 billion. 
Buying $1000 In ALNY: If an investor had bought $1000 of ALNY stock 5 years ago, it would be worth $2,172.18 today based on a price of $322.83 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751292948_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Wells Fargo analyst Tiago Fauth maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Equal-Weight and raises the price target from $287 to $333.

Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $333

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>JP Morgan cut Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) price target from $240 to $230. JP Morgan analyst Samik Chatterjee maintained an Overweight rating. Apple shares closed at $201.56 on Wednesday. S<a href="https://www.benzinga.com/quote/AAPL/analyst-ratings">ee how other analysts view this stock</a>.</li>
<li>Jefferies cut the price target for The Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) from $167 to $145. Jefferies analyst Kaumil Gajrawala maintained a Buy rating. Clorox shares closed at $119.48 on Wednesday. <a href="https://www.benzinga.com/quote/CLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity raised Worthington Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOR#NYSE">WOR</a>) price target from $69 to $81. Canaccord Genuity analyst Brian McNamara maintained a Buy rating. Worthington shares closed at $61.35 on Wednesday. <a href="https://www.benzinga.com/quote/WOR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co boosted the price target for Kymera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) from $54 to $60. HC Wainwright &amp; Co. analyst Andrew Fein maintained a Buy rating. Kymera Therapeutics shares closed at $46.47 on Wednesday. <a href="https://www.benzinga.com/quote/KYMR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo cut the price target for The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) from $74 to $68. Wells Fargo analyst Alec Brondolo downgraded the stock from Overweight to Equal-Weight. Trade Desk shares closed at $69.80 on Wednesday. <a href="https://www.benzinga.com/quote/TTD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup raised Truist Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>) price target from $44 to $55. Citigroup analyst Keith Horowitz upgraded the stock from Neutral to Buy. Truist Financial shares settled at $41.40 on Wednesday. <a href="https://www.benzinga.com/quote/TFC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt raised Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) price target from $172 to $200. Rosenblatt analyst Kevin Cassidy maintained a Buy rating. Micron shares closed at $127.25 on Wednesday. <a href="https://www.benzinga.com/quote/MU/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham increased Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) price target from $320 to $377. Needham analyst Joseph Stringer maintained a Buy rating. Alnylam Pharmaceuticals shares closed at $321.94 on Wednesday.  <a href="https://www.benzinga.com/quote/ALNY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark boosted the price target for Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) from $350 to $475. Benchmark analyst Mickey Legg maintained a Buy rating. Tesla shares settled at $327.55 on Wednesday. <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird increased Concentrix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) price target from $62 to $72. Baird analyst David Koning maintained an Outperform rating. Concentrix shares closed at $54.17 on Wednesday. <a href="https://www.benzinga.com/quote/CNXC/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying TSLA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/TSLA/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="570" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26090911/image-410-1024x570.png" alt="" class="wp-image-963276" style="width:623px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26090911/image-410-1024x570.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26090911/image-410-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26090911/image-410-768x428.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26090911/image-410.png 1162w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46093486/top-2-utilities-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Utilities Stocks That May Fall Off A Cliff In Q2</a> </li>
</ul>
Photo via Shutterstock

AAPL

CNXC

KYMR

TSLA

Tesla To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday

Needham analyst Joseph Stringer maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $320 to $377.

Needham Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $377

BMO Capital analyst Kostas Biliouris maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Outperform and raises the price target from $300 to $360.

BMO Capital Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $360

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 20 years by 12.09% on an annualized basis producing an average annual return of 20.51%. Currently, Alnylam Pharmaceuticals has a market capitalization of $39.93 billion. 
Buying $1000 In ALNY: If an investor had bought $1000 of ALNY stock 20 years ago, it would be worth $40,864.67 today based on a price of $308.54 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750089617_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years

Ratings for Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) were provided by 18 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">11</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">9</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Alnylam Pharmaceuticals, presenting an average target of $339.39, a high estimate of $500.00, and a low estimate of $268.00. Surpassing the previous average price target of $324.29, the current average has increased by 4.66%.
<img src="https://www.benzinga.com/files/images/story/2025/1749736915_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Alnylam Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$338.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Esther Rajavelu</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$349.00</td>
<td>$331.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$325.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Michael Ulz</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$268.00</td>
<td>$284.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$500.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$342.00</td>
<td>$338.00</td>
</tr>
<tr>
<td>Joshua Smith</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Buy</td>
<td>$353.00</td>
<td>-</td>
</tr>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$345.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$328.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>David Lebovitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$351.00</td>
<td>$338.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$390.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$330.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$338.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$287.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$325.00</td>
<td>$302.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Alnylam Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Alnylam Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Alnylam Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Alnylam Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALNY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Alnylam Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Alnylam Pharmaceuticals Better</h2>
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
<h3>Alnylam Pharmaceuticals's Economic Impact: An Analysis</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Alnylam Pharmaceuticals's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 20.2%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Alnylam Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -9.67%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Alnylam Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -62.98%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Alnylam Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.36%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 11.28, caution is advised due to increased financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 18 Analyst Ratings Have To Say About Alnylam Pharmaceuticals

JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Overweight and raises the price target from $330 to $338.

JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $338

Press Releases

Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference

Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress

AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B

Comments

Alnylam Pharmaceuticals

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL